These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 34106616

  • 1. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X, Yang M, Wang L, Li L, Zhong X.
    Medicine (Baltimore); 2021 May 14; 100(19):e25795. PubMed ID: 34106616
    [Abstract] [Full Text] [Related]

  • 2. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 May 14; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 3. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 May 14; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 4. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P, Liu S, Cao H.
    J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005
    [Abstract] [Full Text] [Related]

  • 5. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 22; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 6. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Nov 22; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 7. Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report.
    Li YH, Zhou Y, Liu YY, Zhang GJ, Xiao L, Li N, Qin HF, Wang JG, Zhang L.
    Thorac Cancer; 2021 Jun 22; 12(11):1780-1783. PubMed ID: 33949137
    [Abstract] [Full Text] [Related]

  • 8. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 22; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 9. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
    Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM.
    J Immunother; 2017 Sep 22; 40(6):249-251. PubMed ID: 28557813
    [Abstract] [Full Text] [Related]

  • 10. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
    Ishi A, Tanaka I, Iwama S, Sakakibara T, Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H, Hashimoto N.
    Endocr J; 2021 May 28; 68(5):613-620. PubMed ID: 33790087
    [Abstract] [Full Text] [Related]

  • 11. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
    Patel S, Chin V, Greenfield JR.
    Endocrinol Diabetes Metab Case Rep; 2019 Dec 12; 2019():. PubMed ID: 31829972
    [Abstract] [Full Text] [Related]

  • 12. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.
    Peyrony O, Ellouze S, Fontaine JP, Mohamadou I, Zafrani L.
    Am J Emerg Med; 2020 Feb 12; 38(2):408.e3-408.e4. PubMed ID: 31759780
    [Abstract] [Full Text] [Related]

  • 13. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH, Zhang A, Li LZ, Zhao LC, Wu LX, Fang CT.
    BMC Endocr Disord; 2022 Sep 24; 22(1):239. PubMed ID: 36153581
    [Abstract] [Full Text] [Related]

  • 14. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
    Fu L, Chen P, Wang S, Liu W, Chen Z, Chen H, Fu Z.
    Anticancer Drugs; 2022 Jan 01; 33(1):e741-e746. PubMed ID: 34338239
    [Abstract] [Full Text] [Related]

  • 15. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T, Tontivuthikul B, Sintawichai N, Srichomkwun P.
    J Med Case Rep; 2020 Sep 29; 14(1):171. PubMed ID: 32988414
    [Abstract] [Full Text] [Related]

  • 16. Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.
    Makiguchi T, Fukushima T, Tanaka H, Taima K, Takayasu S, Tasaka S.
    Thorac Cancer; 2022 Apr 29; 13(8):1220-1223. PubMed ID: 35166047
    [Abstract] [Full Text] [Related]

  • 17. Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review.
    Kapagan T, Aksu F, Yuzkan S, Bulut N, Erdem GU.
    J Oncol Pharm Pract; 2024 Jan 29; 30(1):201-205. PubMed ID: 37321205
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
    Huang W, Liu Y, Li M, Xue Y, Bao W, Guo Y.
    Medicine (Baltimore); 2023 Nov 10; 102(45):e35946. PubMed ID: 37960733
    [Abstract] [Full Text] [Related]

  • 20. Anti-PD-1 Therapy-Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma.
    Samoa RA, Lee HS, Kil SH, Roep BO.
    Diabetes Care; 2020 Sep 10; 43(9):2293-2295. PubMed ID: 32616607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.